Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 29.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 220,014 shares of the company's stock after selling 92,035 shares during the quarter. Victory Capital Management Inc. owned approximately 0.74% of Disc Medicine worth $10,811,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Disc Medicine by 96.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,717 shares of the company's stock valued at $281,000 after purchasing an additional 2,813 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock valued at $54,000 after buying an additional 337 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Disc Medicine by 19.5% in the third quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock worth $239,000 after acquiring an additional 793 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Disc Medicine during the second quarter worth about $636,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Disc Medicine during the second quarter valued at about $6,760,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on IRON. Cantor Fitzgerald reissued an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Tuesday, October 15th. HC Wainwright boosted their price objective on shares of Disc Medicine from $70.00 to $118.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Wedbush restated an "outperform" rating and issued a $83.00 target price (up previously from $75.00) on shares of Disc Medicine in a research note on Tuesday, November 12th. Wells Fargo & Company assumed coverage on Disc Medicine in a research note on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price target on the stock. Finally, Scotiabank raised their price objective on Disc Medicine from $62.00 to $70.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 5th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Disc Medicine presently has a consensus rating of "Buy" and a consensus target price of $85.80.

Disc Medicine Stock Up 5.0 %

Shares of NASDAQ IRON opened at $62.55 on Thursday. The firm's 50 day simple moving average is $51.79 and its 200-day simple moving average is $45.73. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.15. Equities analysts predict that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

Insider Transactions at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the business's stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Jacob Savage sold 9,158 shares of the company's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $59.64, for a total transaction of $546,183.12. Following the transaction, the insider now owns 40,405 shares of the company's stock, valued at approximately $2,409,754.20. This trade represents a 18.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,696 shares of company stock valued at $984,058 in the last three months. 4.24% of the stock is currently owned by company insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.